Healthcare Industry News: rituximab
News Release - September 17, 2007
Updated REVLIMID(R) Clinical Results Presented at the 12th International Workshop on Chronic Lymphocytic LeukemiaClinical Data from Ongoing Studies Evaluate REVLIMID in Relapsed or Refractory Chronic Lymphocytic Leukemia
BOUDRY, Switzerland--(HSMN NewsFeed)--Celgene Corporation (NASDAQ: CELG ) announced that clinical data from two ongoing REVLIMID studies in Chronic Lymphocytic Leukemia (CLL) were reported during the 12th International Workshop on Chronic Lymphocytic Leukemia in London on Saturday, September 15, 2007. Chronic Lymphocytic Leukemia is a hematological cancer that affects approximately 75,000-100,000 people in the U.S. About 10,000 new cases of CLL are diagnosed each year and an estimated 5,000 Americans are expected to die of CLL this year. For the EU-5, the prevalence of CLL is estimated to be about 70,000 people with an estimated 11,000 new cases each year.
Asher Channan-Khan, M.D., of the Roswell Park Cancer Institute in Buffalo, NY, enrolled 45 CLL patients, who had at least two prior therapies. Overall response to lenalidomide monotherapy was 58%, of whom 18% achieved a complete remission and 40% partial remission. The median time to best response was 5.9 months with a range of 1.6-18.3 months. Median progression free survival of all enrolled patients was 19.4 months with a range of 1.2-31.8+ months. Of patients with poor prognostic factors with 17p or 11q cytogenetic abnormality, 44% showed a clinical response, while 30% of patients with fludarabine refractory disease showed a clinical response.
The incidence of grade III/IV thrombocytopenia and neutropenia was 45% and 70% respectively. Fifteen percent of the patients experienced febrile neutropenia.
Tumor flare reaction was a common non-hematologic adverse event. The study reported grade I/II tumor flare reaction incidence of 50% and grade III/IV was 8%. Another non-hematolgic adverse event observed, tumor lysis syndrome, had 5% incidence of grade III/IV occurrences.
"In our study, we have seen impressive activity with REVLIMID in CLL patients," said Dr. Channan-Khan. "We continue to investigate the clinical benefits of REVLIMID in CLL to find an optimal dose level to maximize response while maintaining a clinically manageable side effect profile."
Alessandra Ferrajoli, M.D., of The University of Texas M.D. Anderson Cancer Center in Houston, TX studied heavily pretreated CLL patients with progressive disease with a dose less than that explored in the Channan-Khan trial. The overall response rate to single agent lenalidomide among 44 patients was 34%, among which 7% of patients achieved a complete remission, 2% achieved a nodular partial remission and 25% achieved a partial remission. Stable disease was observed in 23% of the patients. Two complete responses and 4 partial responses were observed in patients carrying 11q deletion abnormalities and one partial response was observed in a patient with a 17p deletion. With a median follow-up of 11 months, the median response duration is 12-plus months.
Grade III/IV hematological adverse events observed in the 325 courses included neutropenia (39%), thrombocytopenia (15%) and anemia (3%). Grade III/IV non-hematological adverse events consisted mainly of diarrhea (2%), fatigue (1%) and tumor flare (1%). Additionally, 9 cases of pneumonia, 6 cases of fever of unknown origin and 2 cases of PCP pneumonia were noted. One patient developed disseminated mucormycosis that was fatal (day 22) and another patient died on day 11 of treatment from pneumonia and intracranial bleeding.
About the Trials
The IRB approved Phase II clinical trial at the Roswell Park Cancer Institute was designed to evaluate and investigate the therapeutic potential and safety of REVLIMID® oral monotherapy in patients with relapsed or refractory CLL. Forty-five patients age 42-75 (median age 64) with relapsed or refractory CLL have been enrolled. Sixty-four percent of patients had advanced Rai stage disease and 35.5% had high-risk cytogenetics (17p- or 11q-deletions). Fifty-one percent of patients had fludarabine refractory disease. Patients in the study received 25 mg of REVLIMID orally once daily for 21 days in a four-week cycle until achievement of a complete response. If progressive disease was observed, rituximab was added to lenalidomide.
The study at The University of Texas M.D. Anderson Cancer Center evaluated REVLIMID's activity in CLL in patients who had received prior purine analog-based combinations. Forty-four patients age 49-86 (median age 64) were enrolled. The median number of prior treatments is 5 (range 1-15) and the median beta-2-microglubulin level was 4.3 mg/dL (range 1.6-10.1). Eighty-eight percent of the patients had unmutated IgVH genes and 59% carried a poor prognostic genomic abnormality (17p- or 11q-deletions). Forty-five percent of patients had advanced Rai stage disease, 27% were fludarabine refractory and 51% had received prior alemtuzumab treatment. Patients received 10mg of REVLIMID orally once daily for four weeks, followed by dose escalation by 5 mg every 28 days to a maximum dose of 25mg/day.
Within the EU, Switzerland, Iceland and Norway, REVLIMID® (lenalidomide) is authorized for marketing and, in combination with dexamethasone, is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy.
REVLIMID is currently approved in the United States by the U.S. Food and Drug Administration (FDA) for multiple myeloma patients who have received at least one prior therapy, and for treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. REVLIMID has obtained Orphan Drug designation in the EU, US, Switzerland and Australia for treatment of multiple myeloma, and MDS, and, for CLL in the US.
REVLIMID is an IMiDs® compound, a member of a proprietary group of novel immunomodulatory agents. REVLIMID and other IMiDs compounds continue to be evaluated in over 100 clinical trials in a broad range of hematological and oncological conditions. The IMiDs pipeline is covered by a comprehensive intellectual property estate of issued and pending patent applications in the US, EU and other regions, including composition-of- matter and use patents.
About Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia results from an acquired (not inherited) injury to the DNA of a single cell, a lymphocyte, in the bone marrow. This injury is not present at birth. Scientists do not yet understand what produces this change in the DNA of CLL patients.
This change in the cell's DNA confers a growth and survival advantage on the cell, which becomes abnormal and malignant (leukemic). The result of this injury is the uncontrolled growth of lymphocytic cells in the marrow leading invariably to an increase of abnormal lymphocytes in the blood and the bone marrow. These lymphocytes do not perform their functions as normal ones would and interfere with the production of other blood cells necessary for the normal functioning of the blood, leading to a host of complications like deficiency of the immune system, coagulation problems, swollen lymph nodes, and many other conditions.
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company's website at www.celgene.com.
This release contains forward-looking statements which are subject to known and unknown risks, delays, uncertainties and other factors not under the Company's control, which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by the FDA and other regulatory authorities, and other factors described in the Company's filings with the Securities and Exchange Commission such as our 10K, 10Q and 8K reports.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.